early gastric cancer or gastric adenoma
Conditions
Interventions
Included subjects take Bonoprazan 20mg per day for 21 days.
Included subjects take Bonoprazan 20mg per day for 56 days.
Sponsors
Keio University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 20-85 undergoing gastric ESD for early gastric cancer or gastric adenoma.
Exclusion criteria
Exclusion criteria: 1) Patients with past history of surgery for upper GI tract. 2) Patients with eGFR<30 or on hemodialysis. 3) Patients with uncompensated liver cirrhosis. 4) Patients with severe bleeding tendency. 5) Patients taking systemic NSAIDs or steroid. 6) Patients taking anti-platelet or coagulant drugs. 7) Patients taking PPI or P-CAB continuously at the time of registry. 8) Patients with perforation during ESD. 9) Patients not fulfilling curative criteria by ESD. 10) Patients taking Atazanavir or Rirupibirin. 11) Patients who attending physicians consider to be inappropriate due to other reasons mentioned above
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of complete closure of post ESD ulcer at 24 weeks after gastric ESD. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Proportion of bleeding within 3 weeks after gastric ESD. 2) Proportion of bleeding more than 3 weeks after gastric ESD. 3) Proportion of perforation within 3 weeks after gastric ESD. 4) Proportion of perforation more than 3 weeks after gastric ESD. 5) Proportion of complete closure of post ESD ulcer at 8 weeks after gastric ESD. 6) Status of post ESD ulcer (evaluated based on Sakita Miwa classification) at 8 and 24 weeks after ESD. 7) Medical care cost. | — |
Countries
Japan
Contacts
Public ContactMotohiko Kato
Keio University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine
Outcome results
None listed